Navigation Links
Assurance Biosense, Inc. Receives FDA 510(k) Clearance
Date:4/17/2013

Glastonbury, CT (PRWEB) April 17, 2013

Assurance Biosense Receives FDA 510(k) Clearance to Market Alar Sensor
-Unique Nasal Ala Pulse Oximetry Sensor-
-Alar Sensing Promises High-Levels of Accuracy, Stability and Monitoring Reliability-
-Sensor Compatible with Large, Existing Installed Base of Pulse Oximeters-

Assurance Biosense, Inc., a subsidiary of Xhale, Inc., today announced receipt from the U.S. Food and Drug Administration (FDA) of 510(k) clearance to market its Assurance® Alar Sensor for monitoring of oxygen saturation of arterial hemoglobin (SpO2) and pulse rate from the nasal ala of adult and pediatric patients.

The nasal ala, the fleshy part of the nose adjacent to the opening of the nares (nostril), is a region rich in vasculature and offers a unique monitoring site for pulse oximetry. This site is fed by both the external and internal carotid arteries; the latter also provides blood to the brain. This multi-directional arterial supply provides strong, reliable photoplethysmography signals that are rapidly responsive to changes in the patient’s arterial oxygen saturation. This measurement site is less susceptible to patient movement or loss of signal due to variations in peripheral perfusion as are the extremities, and is easily accessed by an anesthesiologist during surgery.

The Assurance Alar Sensor is intended for the continuous non-invasive monitoring of SpO2 from the nasal ala of adult and pediatric patients (weighing >30kg). The single patient use sensor attaches comfortably to the nasal ala without the need for adhesives at the placement site and can easily be checked and moved by the clinician as necessary, allowing it to remain on the patient for the full length of stay. The sensor is compatible with the large installed base of monitors compatible with the Nellcor Oxisensor-II sensor.

Andrew E. Kersey, President of Assurance Biosense, stated, “We are excited to receive clearance to market our unique Assurance Alar Sensor. We plan to begin initial shipments to select customers over the coming weeks. This revolutionary new sensor offers the benefits of reliable central monitoring while using existing legacy pulse oximeters and at no additional cost to that of traditional disposable finger-tip based oximeter sensors.”

“Clinical testing has shown central monitoring of pulse oximetry to be an improvement over peripheral sites such as the finger-tips used by traditional sensors”, Mr. Kersey continued, “further improving the measurement of this vital sign and improving patient care. Compared to monitoring at the finger-tip, central pulse oximetry has been shown to offer reliable measurements during extremely low perfusion, as well as faster detection of desaturation and resaturation events particularly during low perfusion. The nose is an excellent site for ease of access during surgery, while the hands are not readily available to anesthesiologists. This first product in our portfolio will be an important foundation upon which we will add future products that capitalize on the benefits of measurement at the alar site.”

About Assurance Biosense:
Assurance Biosense, a wholly owned subsidiary of Xhale, Inc., is committed to providing clinicians with easy to use, cost effective diagnostic solutions that improve patient safety and reduce false alarms. Its Assurance PPG/oximetry sensors monitor central blood flow to the brain through placement on the nasal ala, a region rich in vasculature, fed by the external and internal carotid arteries. The unique physiology of the site provides a much stronger signal than that from a fingertip or extremity, delivering more robust pulse oximetry signals, while simultaneously enabling the monitoring of a range of critical physiologic parameters which cannot be monitored via conventional pulse oximetry.

About Xhale:
Xhale, Inc. is a medical technology innovator, developing products that transform healthcare and save lives. The company is a world leader in the use of sensors that analyze vapor and exhaled breath and is focused on novel patient-centric monitoring solutions. Its current product lines include SMART®, the world’s only definitive medication adherence monitoring system, and Assurance®, a replacement for conventional finger-based pulse oximetry which will monitor multiple patient parameters from a single-point-of-contact sensor more comfortably and conveniently, and with fewer false alarms, than finger-based pulse oximetry.

For more information, please visit http://www.assurancebio.com or contact Investor Relations at the company at ir(at)xhale(dot)com or 352.371.8488.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10640692.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Chemical Publishing Company; Author Colin Frayne of Aquassurance Inc. To Conduct Service Technician Training Course
2. UCSB professor receives award for graphene electronics research
3. Watsons Generic Yaz(R) Receives FDA Approval
4. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
5. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
6. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
7. Intimate Bridge 2 Conception, Inc. Receives $4.3M
8. Pacific Meso Center Receives Generous Donation to First Free-Standing Mesothelioma Research Laboratory in Los Angeles
9. BioNeutral Group Receives $400,000 in Equity Financing
10. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
11. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 22, 2017 , ... AESKU.GROUP, ... DST Diagnostische Systeme & Technologien GmbH, thereby expanding its product portfolio to include ... hay fever, urticaria, asthma, atopic eczema or a food allergy. Allergies are escalating ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... release of Limfinity® version 6.5, a content-packed update to the Limfinity® framework. , ... a larger and more diverse base of customers among labs and other businesses. ...
(Date:6/20/2017)...  Kibow Biotech Inc., a pioneer in developing "Enteric ... a new patent covering a unique method for preventing ... and Trademark Office on May 23 rd 2017. ... Bio award in 2014 in San Diego, ... to chronic disease. Renadyl™, the first and only dietary ...
(Date:6/19/2017)... ... June 19, 2017 , ... EDETEK, Inc., a clinical technology ... is launching two new additions of its award-winning cloud-based platform CONFORM™: Information Hub ... DIA 2017 Annual Meeting in Chicago, IL, June 19-22, 2017. , “Modern clinical ...
Breaking Biology Technology:
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
Breaking Biology News(10 mins):